Lexaria's DehydraTECH platform can take existing formulations & improve their delivery & safety. CEO Rich Christopher looks at the oral & injectable opportunities inside & outside the diabetes & weight loss spaces.
#$LEXX
#OralGLP1 #OralDeliveryTech #MetabolicTherapy
youtube.com/shorts/vE7bq...

Full Length Version.
Join Lexaria Bioscience CEO Rich Christopher for a review of the company's GLP-1 agonist studies, business development activities & future opportunities for oral drug development.
#$LEXX
youtu.be/GtFIPq0IReo
#OralGLP1 #OralDeliveryTech #GLP1Innovation

CEO Richard Christopher describes where Lexaria has done the most work in the GLP-1 agonist space, combining both injectable API and crushed oral tablets with DehydraTECH.
#$LEXX
#OralGLP1 #OralDeliveryTech #GLP1Agonist #GLP1Innovation #MetabolicTherapy
youtube.com/shorts/sG7Xj...

Lexaria Bioscience CEO Richard Christopher summarizes details from $LEXX human clinical trials evaluating #DehydraTECH & GLP1 agonists along with the technology’s key benefits.
#LexariaBioscience #LexariaDelivery #NextGenDrugDelivery #OralDeliveryTech #OralPeptideDelivery #GLP1Therapy #GLP1Agonist